
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
EVOLUS INC. DL-,00001 EVL US30052C1071 BAW/UFN
© 2025 Xetra Newsboard
Realtime | Geld | Brief | Zeit |
---|---|---|---|
13,500 | 13,700 | 09:49 | |
13,500 | 13,600 | 09:42 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
14.02. | Breaking Down Evolus: 4 Analysts Share Their Views | ||
13.02. | Evolus wins approval for hyaluronic acid dermal fillers | ||
13.02. | XFRA EVL: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
13.02. | XFRA EVL: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEVOLUS INC. DL-... ► Artikel lesen | |
13.02. | Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels | NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration... ► Artikel lesen |